Data collection on rare bone and mineral conditions in Europe: The landscape of registries and databases.


Journal

European journal of medical genetics
ISSN: 1878-0849
Titre abrégé: Eur J Med Genet
Pays: Netherlands
ID NLM: 101247089

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 04 05 2023
revised: 19 09 2023
accepted: 15 10 2023
medline: 4 6 2024
pubmed: 4 6 2024
entrez: 4 6 2024
Statut: ppublish

Résumé

knowledge on the natural history of rare diseases is necessary to improve outcomes. Disease registries may play a key role in covering these unmet needs in the rare bone and mineral community. to map existing bone and mineral conditions registries in Europe and their characteristics. online survey about the use of registries/databases and their characteristics. This survey was disseminated among members of the European Reference Network on Rare Bone Diseases (ERN BOND) and non-ERN experts in the field of bone and mineral conditions as well as patient organisations. sixty-three responses from health care providers (HCPs) and 10 responses from patient groups (PGs) were collected. The response rate for ERN BOND members was 55%. Of 63 HCPs, 37 declared using a registry. Osteogenesis imperfecta (OI) was the most registered condition. We mapped 3 international registries, all were disease-specific. There is a need for developing a common high-quality platform for registering rare bone and mineral conditions.

Sections du résumé

BACKGROUND BACKGROUND
knowledge on the natural history of rare diseases is necessary to improve outcomes. Disease registries may play a key role in covering these unmet needs in the rare bone and mineral community.
OBJECTIVE OBJECTIVE
to map existing bone and mineral conditions registries in Europe and their characteristics.
METHODS METHODS
online survey about the use of registries/databases and their characteristics. This survey was disseminated among members of the European Reference Network on Rare Bone Diseases (ERN BOND) and non-ERN experts in the field of bone and mineral conditions as well as patient organisations.
RESULTS RESULTS
sixty-three responses from health care providers (HCPs) and 10 responses from patient groups (PGs) were collected. The response rate for ERN BOND members was 55%. Of 63 HCPs, 37 declared using a registry. Osteogenesis imperfecta (OI) was the most registered condition. We mapped 3 international registries, all were disease-specific.
CONCLUSIONS CONCLUSIONS
There is a need for developing a common high-quality platform for registering rare bone and mineral conditions.

Identifiants

pubmed: 38832910
pii: S1769-7212(23)00174-X
doi: 10.1016/j.ejmg.2023.104868
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104868

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no competing interests.

Auteurs

Ana Luisa Priego Zurita (AL)

Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Centre, Leiden, Netherlands. Electronic address: a.l.priego_zurita@lumc.nl.

Corinna Grasemann (C)

Department of Pediatrics, Division of Rare Diseases, Ruhr-University Bochum, Bochum, Germany.

Manila Boarini (M)

Department of Rare Skeletal Disorders, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.

Roland Chapurlat (R)

INSERM UMR, 1033 and Université de Lyon, Lyon, France.

Marina Mordenti (M)

Department of Rare Skeletal Disorders, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
European Reference Network on Rare Bone Diseases, Italy.

Muhammad Kassim Javaid (MK)

NDORMS, University of Oxford, Oxford, United Kingdom.

Natasha M Appelman-Dijkstra (NM)

Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Centre, Leiden, Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH